Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
Palabras clave : 
Immunotherapy
Chekpoint inhibitors
Cancer vaccines
Adoptive cell transfer combination therapy
Biomarkers
Fecha de publicación: 
2018
ISSN: 
2051-1426
Nota: 
This is an open access article distributed under the Creative Commons: Atribution License (cc BY)
Cita: 
Ascierto, P. A.; Brugarolas, J.; Buonaguro, L.; et al. "Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)". Journal for immunotherapy of cancer 6, 2018, 69
Resumen
Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.

Ficheros en este registro:
Fichero: 
pdf.pdf
Descripción: 
Tamaño: 
980,27 kB
Formato: 
Adobe PDF


Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.